New European sites in Immunovia’s PanFAM-1, the largest ever prospective multicenter clinical study for early detection of pancreatic cancer
New centers in Sweden and Spain broaden sample ethnic and racial diversity in drive to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.LUND, SWEDEN ― Immunovia AB today announced that two additional sites, Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, are now part of PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s